RxDoctor Payments Data

Joseph Cochran, MD

Gastroenterology · Birmingham, ALNPI 1386628428

Payments from drug & device makers

$7,636in general payments, 2019–2025

Across 417 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$907
  • Takeda Pharmaceuticals U.S.A., Inc.$524
  • Bristol Myers Squibb$395
  • Gilead$383
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,53699%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,636 in reported general payments places this provider in the 65th percentile of 225 gastroenterology providers in Alabama.

See all gastroenterology providers in Alabama

Medicare billing

Part B allowed, 2024
$187,222
Medicare patients
403
Services billed
3,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$473,517
Humira(Cf) PenAdalimumab19$259,039
LinzessLinaclotide66$43,656
ZenpepLipase/Protease/Amylase16$27,342
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C110$14,859
Ursodiol43$10,353
Dexlansoprazole DrDexlansoprazole17$5,867
Lubiprostone23$5,345
SutabSod Sulf/Pot Chloride/Mag Sulf32$5,068
Tenofovir Disoproxil Fumarate27$3,091
Famotidine215$2,685
Pantoprazole Sodium225$2,389
LoperamideLoperamide Hcl18$1,782
Colestipol Hcl24$1,694
Budesonide DrBudesonide13$1,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,251$473,51717 claims
AbbVieLinzess$1,626$43,65666 claims
Aimmune Therapeutics, Inc.Zenpep$105$27,34216 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$907$14,859110 claims
Braintree Laboratories, Inc.Sutab$34$5,06832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 225 gastroenterology providers in Alabama.

Other gastroenterology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →